LISA Post Market Clinical Follow-Up Study: Documentation of Clinical Outcomes After Surgery With LISA Implant

NCT ID: NCT04631133

Last Updated: 2022-07-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

136 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-04-17

Study Completion Date

2028-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study is a post-market surveillance study of the Lumbar Implant for Stiffness Augmentation (LISA), a medical device, which is used to treat low-back pain that accompanies degenerative lesions of grades II, III, and IV (Pfirrmann MRI classification). "Post-market" means the device (i.e. the LISA implant) being used in this study has already obtained CE certification and is commercially available for use in the European market.

The LISA device consists of 3 components: A PEEK interspinous spacer, a polyester band, and a titanium blocker. The spacer is positioned between two adjacent spinous processes, the band is belted around the spinous processes and through the spacer, and the blocker is used to lock the band inside the spacer.

Medical Device manufacturers conduct "post-market" clinical studies in order to continuously evaluate the product scientifically and to comply with legal and ethical obligations. With these studies, the long-term safety as well as performance of their medical devices are assessed.

This study, which is initiated and sponsored by BACKBONE (LISA designer, developer, manufacturer and marketer), aims to evaluate the long-term safety and performance of the LISA implant for the treatment of lumbar degenerative disease and to evaluate the treatment.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Low-back Pain Herniated Disc Degenerative Disc Disease Lumbar Canal Stenosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Participants with low-back pain and degenerative lesions of grade II, III, IV (Pfirrmann MRI class)

Participants with low-back pain that accompanies degenerative lesions of grade II, III and IV (Pfirrmann MRI classification)

Lumbar Implant for Stiffness Augmentation (LISA)

Intervention Type DEVICE

The LISA Posterior Dynamic Stabilization System is intended to treat low-back pain that accompanies degenerative lesions of grade II, III and IV (Pfirrmann MRI classification).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lumbar Implant for Stiffness Augmentation (LISA)

The LISA Posterior Dynamic Stabilization System is intended to treat low-back pain that accompanies degenerative lesions of grade II, III and IV (Pfirrmann MRI classification).

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Skeletally mature patients Patient ≥18 years of age
* Patients with low-back pain caused by degenerative lesions of grade II, III and IV (Pfirrmann MRI classification)
* Failed conservative treatment for low back pain conducted for at least 6 months

Exclusion Criteria

* Stage V degenerative disk lesions in Pfirrmann's MRI classification
* Spondylolisthesis
* Osteoporosis
* Non-specific back pain
* Modic 2 and Modic 3 changes
* L5/S1 segments affected
* Local or general infections that may compromise the surgical goals
* Major local inflammatory phenomena
* Pregnant and lactating Women
* Immunosuppressive diseases
* Bone immaturity
* Severe mental illnesses
* Bone metabolism diseases that may compromise the mechanical support expected from this type of implant
* Patient with worker's compensation, under litigation or on disability benefits
* Excessive physical activities
* Patients deprived of their liberty in accordance with respective national regulations
* Protected patients or patients not in a position to declare his or her consent in accordance with respective national regulations
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

BACKBONE

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Vincent Pointillart

Role: PRINCIPAL_INVESTIGATOR

Pellegrin University Hospital Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Elective Surgery Center, Silkeborg Regional Hospital

Silkeborg, , Denmark

Site Status RECRUITING

Pellegrin University Hospital Center

Bordeaux, , France

Site Status RECRUITING

Saint-Charles Clinic

Lyon, , France

Site Status RECRUITING

Pitié-Salpêtrière University Hospital Center

Paris, , France

Site Status RECRUITING

Asklepios Stadtklinik, Bad Wildungen

Bad Wildungen, , Germany

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Denmark France Germany

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Aurélie Affret

Role: CONTACT

0033686114973

Nazanine Sahami

Role: CONTACT

0033646592539

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Aurélie Affret, PhD

Role: primary

0033686114973

Aurélie Affret, PhD

Role: primary

0033686114973

Aurélie Affret, PhD

Role: primary

0033686114973

Aurélie Affret, PhD

Role: primary

003368614973

Aurélie Affret, PhD

Role: primary

0033686114973

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

DHF-111-PMCF1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

OLIF25™ /OLIF51™ Study
NCT02657421 TERMINATED
Clariance ErYs Registry
NCT05170815 RECRUITING